Abstract Search

ea0016p467 | Neuroendocrinology | ECE2008

Starting dose of 10 mg Octreotide-LAR appears ineffective for biochemical control in the majority of acromegalic patients: interim analysis from the OASIS trial

Petersenn Stephan , Tarasov Alexander , Gu Feng , Kim Sungwoon , Mercado Moises , Rogozinski Amelia , Bouterfa Hakim , David Kristin , Silva Antonio , Greenman Yona

Octreotide LAR (SMS-LAR) is available in 10, 20 and 30 mg dosing. The relation-ship between SMS-LAR starting dose and GH, IGF-I and symptoms was exam-ined. The Observational Acromegaly Study on Impact of Sandostatin LAR (OASIS) collects data on GH, IGF-I, symptoms, safety and tolerability in recently diagnosed acromegalic patients. Data are collected under normal practice conditions over 12 mos. Eight hundred and sixty patients from 138 centers in 23 countries are enrolled; 35...

0 shares

ea0011p433 | Endocrine disruptors | ECE2006

A randomized, open-label, multicenter study to evaluate octreotide LAR with surgical therapy as primary therapy patients with acromegaly

Colao A , Bouterfa H , Cappabianca P , Caron P , De Menis E , Farrall A , Gadelha M , Reed A , Reincke M , Safari M , T’Sjoen G , Cuneo R

This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...

0 shares

ea0014p550 | (1) | ECE2007

OASIS: observational study on the international clinical practice for the treatment of recently diagnosed acromegalic patients

Portocarrero Lesly , Akçay Güngör , Bouterfa Hakim , Carvalho Davide , Greenman Yona , Gu Feng , Guitelman Mirtha A , Kim Sungwoon , Kriesche Christine , Mercado Moises , Shen Chiung-Chi , Silva Antonio , Varela Cesar , Wallaschofski Henri , Webb Susan

Background: There is significant interest in how the use of different treatment regimens (e.g. surgery, medical therapy) impacts the clinical course of Acromegaly. This study has been designed to better understand clinical decision making in the context of various treatment options.Methods: OASIS is an international, observational study in recently diagnosed acromegalic patients. Ethical committee approval was obtained where applicable. Observations incl...

0 shares

Endocrine Abstracts

Starting dose of 10 mg Octreotide-LAR appears ineffective for biochemical control in the majority of acromegalic patients: interim analysis from the OASIS trial

A randomized, open-label, multicenter study to evaluate octreotide LAR with surgical therapy as primary therapy patients with acromegaly

OASIS: observational study on the international clinical practice for the treatment of recently diagnosed acromegalic patients

BiosciAbstracts